TORONTO, May 18, 2020 (GLOBE NEWSWIRE) — Buzz Capital Inc. (TSXV: BUZ.P) (“Buzz Capital” or the “Corporation”), a capital pool company listed on the TSX Venture Exchange (the “Exchange“), is pleased to announce that it has signed a letter of intent dated May 8, 2020 (the “Letter of Intent“) with Novamind Ventures Inc., an Ontario corporation, (“Novamind”) to complete a business combination by way of a transaction that will constitute a reverse takeover of Buzz Capital by Novamind. The proposed transaction is intended to constitute an arm’s length qualifying transaction (the “Qualifying Transaction“) for Buzz Capital, as defined in Policy 2.4 of the Exchange. Upon completion of the Qualifying Transaction and the Financing (as defined and described below), it is expected that Buzz Capital (following the Qualifying Transaction, the “Resulting Issuer”) will be a Tier 2 Industrial Issuer, subject to Exchange approval.
Description of Novamind
Novamind invests in the infrastructure that drives the world’s leading psychedelic clinics and retreats. Novamind was founded in May 2019 in Toronto, Canada.
Ongoing clinical trials approved by the U.S. Food and Drug Administration (“FDA”) are currently evaluating the safety and efficacy of MDMA-assisted psychotherapy (to treat PTSD) and psilocybin-assisted psychotherapy (to treat depression), and if approved, will require specialized infrastructure to facilitate patient treatment. Novamind seeks to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry.
Until such time that the FDA approves new psychedelic medicines, Novamind invests and operates exclusively in those jurisdictions with established legal regulations for the use of psychedelics. With this as a prerequisite, Novamind was an early mover in 2019 and made two strategic investments in industry-leading psychedelic retreats and clinics:
- a €750,000 (CAD $1,137,623) investment in Synthesis Institute B.V. (“Synthesis”), a Netherlands-based psychedelics retreat offering an interdisciplinary approach to safe, legal psilocybin experiences. The investment in Synthesis was funded in cash and closed in multiple tranches beginning in November 2019 with the final tranche completed in March 2020; and
- a letter of intent to purchase 100% of the assets of Cedar Psychiatry LLC and Cedar Clinical Research LLC (“Cedar Psychiatry”), a leading provider of psychedelic-assisted psychotherapy and research, based in the United States (the “Cedar Acquisition”). Cedar Psychiatry operates three psychiatry clinics specialized in ketamine-assisted psychotherapy, and a dedicated research center that conducts novel clinical trials. Novamind’s acquisition of Cedar Psychiatry is expected to close prior to the Qualifying Transaction. The purchase price for the Cedar Psychiatry acquisition is $3,050,000 consisting of 5,125,000 Novamind Consolidated Shares (as defined below) to be issued at a deemed price of $0.40 per share and cash payments totalling $1,000,000 to be paid over 12 months from closing of the Cedar Acquisition.
Novamind’s investment in Synthesis and its acquisition (pending) of Cedar Psychiatry provides Novamind with access to proprietary resources including psychedelic-assisted psychotherapy protocols, industry-leading data, patient screening tools, leading facilitators and scientific advisors. Utilizing these best practices and partnering with leading practitioners in the psychedelic space, Novamind is building a network of clinics and retreats offering people access to safe, legal psychedelic experiences while advancing research for psychedelic medicine.
Additional information on Novamind will be provided in the filing statement to be filed pursuant to the Qualifying Transaction.
The Qualifying Transaction
The Letter of Intent contemplates that the Qualifying Transaction will be undertaken by way of a three-corner amalgamation, pursuant to which Novamind will amalgamate (the “Amalgamation“) with a newly formed subsidiary of Buzz Capital and, as such, approval of the Novamind shareholders (“Novamind Shareholders”) will be required. Upon completion of the Amalgamation, the corporation formed by the amalgamation of Novamind and the newly-formed subsidiary of Buzz Capital will be a wholly-owned subsidiary of Buzz Capital.
Prior to the Amalgamation, Buzz Capital will effect a consolidation (the “Buzz Consolidation”) and Novamind will similarly effect a consolidation (the “Novamind Consolidation”; together with the Buzz Consolidation, the “Consolidations”) of, respectively, the issued and outstanding common shares of Buzz Capital (the “Buzz Shares”) and Novamind (the “Novamind Shares”). Under the Buzz Consolidation, the Buzz Shares will be consolidated on a basis that results in the holders of Buzz Shares (“Buzz Shareholders”) holding post-Buzz Consolidation Buzz Shares (“Buzz Consolidated Shares”) having a value of $1,700,000, provided that Buzz Capital has net cash of minimum $500,000 at closing. Assuming a net cash position of a minimum of $500,000, this would result in the Buzz Shares being consolidated on a 1:1.9788 basis, resulting in approximately 4,250,000 Buzz Consolidated Shares being outstanding. Under the Novamind Consolidation, the outstanding Novamind Shares will be consolidated on a 1:4 basis, resulting in Novamind Shareholders holding approximately 19,018,750 post-Novamind Consolidation Novamind Shares (“Novamind Consolidated Shares”). The number and exercise prices of the outstanding convertible securities of Buzz Capital (“Buzz Convertible Securities”) and Novamind (“Novamind Convertible Securities; together with the Buzz Convertible Securities, the “Convertible Securities”) will be adjusted in accordance with their terms as a result of, respectively, the Buzz Consolidation and Novamind Consolidation.
Following the Consolidations and pursuant to the Amalgamation, the holders of Novamind Consolidated Shares immediately prior to the completion of the Amalgamation will each receive, for every one (1) Novamind Consolidated Share held immediately prior to the completion of the Amalgamation, one (1) Buzz Consolidated Share (the “Exchange Ratio”). Outstanding Novamind Convertible Securities will either automatically adjust in accordance with the terms thereof such that following the completion of the Amalgamation, the holders thereof shall acquire Buzz Consolidated Shares in lieu of Novamind Consolidated Shares or will be replaced with equivalent convertible securities of Buzz entitling the holders thereof to acquire Buzz Consolidated Shares in lieu of Novamind Consolidated Shares, and otherwise bearing the same terms as the Novamind Convertible Securities which they replace.
Completion of the Qualifying Transaction is subject to the satisfaction of a number of conditions, including, but not limited to:
- a change in the name of Buzz Capital to “Novamind Inc.” or such other name as may be approved by Novamind and acceptable to applicable regulatory authorities;
- receipt of all necessary third-party, regulatory and Exchange approvals, including the approval by the Exchange of the proposed transaction as Buzz Capital’s Qualifying Transaction;
- negotiation and execution and delivery of a definitive form of amalgamation agreement (the “Definitive Agreement“) mutually acceptable to both Novamind and Buzz Capital, containing the terms and conditions customary in transactions of like nature;
- approval of the Amalgamation and the Definitive Agreement by the board of directors of Novamind and Buzz Capital;
- prior to the Qualifying Transaction, the completion by Novamind of the Financing (as defined below); and
- the approval of the Amalgamation by the Novamind shareholders.
Selected Financial Information of Novamind
The following tables sets out unaudited historical financial information of Novamind for the period commencing on its date of incorporation, May 22, 2019 and ending April 30, 2020.
|Balance Sheet Account||As at April 30, 2020|
|Total Shareholder’s Equity||$2,352,407|
|Income Statement||May 22, 2019 to April 30, 2020|
In connection with the Qualifying Transaction and prior to the Novamind Consolidation, Novamind is undertaking a non-brokered private placement (the “Financing”) of Novamind Shares at a price of $0.10 per share for minimum gross proceeds of $2,500,000. Novamind engaged First Republic Capital Corporation (“First Republic”) as its exclusive lead finder in connection with the Financing. As compensation, First Republic will be paid a cash commission equal to 7% of the aggregate gross proceeds of the Financing and compensation warrants (“Compensation Warrants”) equal to 7% of the number of Novamind Shares issued under the Financing. Each Compensation Warrant entitles the holder to acquire a Novamind Share at an exercise price of $0.10 for a period of 24 months following the closing date of the Financing. The Novamind Consolidation will result in the number of Novamind Shares and Compensation Warrants issued in the Financing being divided by four, and the effective offering price under the Financing and the exercise price of the Compensation Warrants being adjusted to $0.40 per share. Novamind has closed a first tranche of the Financing for gross proceeds of $1,607,500.
Pro Forma Capitalization
The table below demonstrates the anticipated non-diluted capitalization of the Resulting Issuer post Qualifying Transaction and Financing, assuming completion of the minimum Financing, and lists the number of common shares of the Resulting Issuer (“Resulting Issuer Shares”) anticipated to be held by the Buzz Shareholders, Novamind Shareholders and investors in the Financing.
|Number of Resulting Issuer Shares Issued and Outstanding Post-Qualifying Transaction Assuming Minimum Financing and completion of the Consolidations||Percentage of Resulting Issuer Shares Post-Qualifying Transaction Assuming Minimum Financing and completion of the Consolidations|
|Resulting Issuer Shares held by Buzz Capital Shareholders||4,250,000||13.88%|
|Resulting Issuer Shares held by Former Novamind Shareholders(1)||15,000,000||48.98%|
|Resulting Issuer Shares held by Former Cedar Psychiatry Shareholders||5,125,000||16.73%|
|Resulting Issuer Shares held by investors in the Financing(1)||6,250,000||20.41%|
- Novamind has raised aggregate gross proceeds of $1,607,500 under the Financing to date and has issued 16,075,000 Novamind Shares, which, following the Novamind Consolidation, will be consolidated into approximately 4,018,750 Novamind Consolidated Shares. These 4,018,750 Novamind Consolidated Shares are included in the row titled “Resulting Issuer Shares held by investors in the Financing”, which discloses the number of Novamind Consolidated Shares that would be outstanding if Novamind raised an additional $892,500 under the Financing, being an amount sufficient to meet the minimum $2,500,000 Financing.
It is anticipated that proceeds from the Financing will be used for acquisitions and for general working capital.
Board of Directors, Officers and other Insiders
Upon completion of the Qualifying Transaction, it is anticipated that the board of directors and officers of the Resulting Issuer will be comprised of the individuals listed below. In addition, the parties anticipate that Novamind will nominate the Chief Financial Officer and Corporate Secretary of the Resulting Issuer. The identities and biographies of these individuals will be disclosed in a subsequent press release or filing statement prepared in connection with the Qualifying Transaction. To the knowledge of Novamind and Buzz Capital, no person will beneficially own, directly or indirectly, or exercise control or direction over, more than 10% of the Resulting Issuer.
Chuck Rifici (Director), Ottawa, Ontario
Chuck is a pioneer of the North American cannabis industry, having created and managed opportunities which have had an incredible and widespread impact on the Canadian cannabis landscape. The founder of Canopy Growth (FKA Tweed Marijuana), Chuck is Chairman of Auxly Cannabis Group, Chairman at Feather Company and is a chartered professional accountant (CPA). He obtained his MBA from Queen’s University and holds a BASc in Computer Engineering from the University of Ottawa.
Yaron Conforti (Chief Executive Officer and Director), Toronto, Ontario
Yaron Conforti is the founder and principal of Emmcap Corp., an investor in venture-stage companies. He previously served in senior investment banking roles at Desjardins Securities and Sandfire Securities and in CEO, CFO and corporate director roles for private and public companies.
Jesse Kaplan, CFA (Director), Toronto, Ontario
Jesse Kaplan has been a partner with Plaza Capital Limited since 2015. His career has focused on advising and investing in early stage growth companies. This has included extensive work helping companies through the process of going public in both Canada and the United States. Jesse was previously a senior analyst at Harborview Advisors LLC, a New York based investment firm and Palladium Capital Advisors, LLC, a NASD member investment bank. Currently, he is a board member of Abacus Health Products (CSE:ABCS) among other successful companies.
Sruli Weinreb (Director), Toronto, Ontario
Sruli Weinreb is the founder and managing partner of Plaza Capital Limited. Plaza Capital supports many North American early stage growth companies with strategic debt placements and equity investments. He is also the chief executive officer of Lake Central Air Services Inc., the world’s leading modification and integration partner for the airborne geophysical survey industry. Before founding Plaza Capital in 2013, Sruli was the chief executive officer of eMobile Inc., a telecom arbitrage company with a specialization in international roaming which he co-founded in 2008.
Sponsorship of a qualifying transaction of a capital pool company is required by the Exchange unless exempt in accordance with Exchange policies. Buzz Capital is currently reviewing the requirements for sponsorship and may apply for an exemption from the sponsorship requirements pursuant to the policies of the Exchange; however, there is no assurance that Buzz Capital will ultimately obtain this exemption. Buzz Capital intends to include any additional information regarding sponsorship in a subsequent press release.
The Buzz Shares are currently halted from trading on the Exchange and will remain halted until such time as determined by the Exchange, which, depending on the policies of the Exchange, may or may not occur until the completion of the Qualifying Transaction.
All information contained in this news release with respect to Novamind and Buzz Capital was supplied by the parties respectively, for inclusion herein, and each party and its directors and officers have relied on the other party for any information concerning the other party.
Completion of the transaction is subject to a number of conditions, including, but not limited to, Exchange acceptance and if applicable pursuant to Exchange requirements, majority of the minority shareholder approval.
Where applicable, the transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.
Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Buzz Capital Inc.
For further information:
Buzz Capital Inc.
CEO, CFO and Director
Tel: (613) 239-0531
Novamind Ventures Inc.
CEO and Director
Tel: (647) 953-9512
Website: Where Can I Buy Valium In Canada
LAST ALERT MADE MORE THAN 360% TO DATE !
Valium 2Mg Online, Buy Diazepam 10Mg
This article is written and published by The Cannabis Stock
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies
The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.